Japan Hemophilia Treatment Market Set to Worth Over US$ 937.37 Million by 2033 | Astute Analytica
Hemophilia treatment market is driven by aging populations increasing acquired cases, government-backed early diagnosis, and pediatric prophylaxis adoption. Hemophilia A dominates (74.43%), with extended half-life factors and gene therapies boosting efficacy, despite high costs straining insurance systems and rural care gaps.
Chicago, March 24, 2025 (GLOBE NEWSWIRE) — As per the newest research from Astute Analytica, the Japan hemophilia treatment market was valued at US$ 556.69 million in 2024 and is expected to reach US$ 937.37 million by 2033, growing at a CAGR of 6.16% during the forecast period 2025–2033.
The demand for hemophilia treatment in Japan has been steadily expanding, driven by several key factors that reflect both medical advancements and societal changes. One of the primary drivers is the increasing life expectancy of hemophilia patients, which has risen significantly due to improved treatment options and better management protocols. As patients live longer, the cumulative demand for lifelong treatment increases, putting pressure on the healthcare system to provide continuous and evolving care. Additionally, the growing awareness among patients and healthcare providers about the importance of prophylactic treatment has led to a shift from on-demand therapy to regular preventive measures, further boosting the demand for hemophilia treatment market.
Download Free Sample Pages: https://www.astuteanalytica.com/request-sample/japan-hemophilia-treatment-market
Another significant factor contributing to the expanding demand is the introduction of novel therapies, particularly non-factor treatments and gene therapies. These innovative approaches have opened up new possibilities for patients who were previously difficult to treat, such as those with inhibitors to traditional factor replacement therapies. The promise of potentially curative treatments has also increased patient engagement with the healthcare system, as more individuals seek access to cutting-edge therapies. Furthermore, Japan’s aging population and the subsequent increase in acquired hemophilia cases among older adults have added to the overall demand for hemophilia treatments, necessitating a broader range of therapeutic options to address the diverse needs of patients across different age groups.
Key Findings Japan Hemophilia Treatment Market
| Market Forecast (2033) | US$ 937.37 million |
| CAGR | 6.16% |
| By Type | Hemophilia A (74.43%) |
| By Product | Recombinant coagulation factor concentrates (55.61%) |
| By Patient | Pediatric (63.80%) |
| By Treatment Type | On-Demand Treatment (45.31%) |
| By Route of Administration | Intravenous (73.94%) |
| By End User | Hospitals (47.78%) |
| By Distribution Channel | Hospital Pharmacies (51.41%) |
| Top Drivers |
|
| Top Trends |
|
| Top Challenges |
|
Current Prevalence of Hemophilia in Japan
The prevalence of hemophilia in Japan hemophilia treatment market has been closely monitored through comprehensive national surveys and registries. As of 2025, the estimated prevalence of hemophilia A in Japan stands at approximately 5,750 cases, reflecting a slight increase from previous years due to improved diagnostic capabilities and patient longevity. Hemophilia B, while less common, affects around 1,200 individuals in the country. These figures translate to a prevalence rate of about 4.5 cases per 100,000 population for hemophilia A and 0.9 cases per 100,000 for hemophilia B, aligning closely with global prevalence estimates.
The demographic distribution of hemophilia in Japan hemophilia treatment market shows a predominance in males, consistent with the X-linked inheritance pattern of the disorder. Approximately 98% of registered hemophilia patients are male, with a small percentage of female carriers exhibiting symptoms due to lyonization or other genetic factors. Age-wise distribution indicates that about 30% of patients are under 18 years old, 45% are between 18 and 50 years, and 25% are over 50 years of age. This age distribution highlights the success of early diagnosis and treatment programs, as well as the improved life expectancy of hemophilia patients in Japan. The prevalence of inhibitors, a significant complication in hemophilia treatment, is observed in about 25% of severe hemophilia A patients and 3% of hemophilia B patients, underscoring the need for specialized treatment approaches for this subgroup.
Prominent Types of Hemophilia in Japan: Distribution and Characteristics
In Japan, the landscape of hemophilia treatment market is dominated by two main types: Hemophilia A and Hemophilia B, with Hemophilia A being significantly more prevalent. As of 2025, Hemophilia A accounts for approximately 84% of all hemophilia cases in Japan, affecting around 5,750 individuals and generating more than 74% market revenue. This type is characterized by a deficiency in clotting factor VIII and presents with a spectrum of severity levels. Severe cases, defined by factor VIII levels less than 1% of normal, comprise about 60% of Hemophilia A patients in Japan, requiring intensive management and regular prophylactic treatment. Moderate cases (1-5% factor VIII activity) and mild cases (5-40% factor VIII activity) make up the remaining 40%, often requiring less frequent interventions but still necessitating careful monitoring and treatment plans.
Hemophilia B, resulting from a deficiency in clotting factor IX, is less common, affecting approximately 1,200 individuals in Japan hemophilia treatment market, or about 16% of the total hemophilia population. The severity distribution in Hemophilia B is similar to that of Hemophilia A, with severe cases accounting for about 50% of patients. A unique aspect of hemophilia management in Japan is the high rate of diagnosis and treatment of mild cases, which is attributed to the country’s comprehensive healthcare system and advanced diagnostic capabilities. This has led to a more complete picture of the hemophilia landscape, including the identification of rare variants and acquired forms of the disorder. Acquired hemophilia, while not genetically inherited, has seen an increase in prevalence, particularly among the elderly population, with an estimated 100 new cases diagnosed annually in Japan. This trend has prompted the development of specialized treatment protocols and increased awareness among healthcare providers to ensure timely diagnosis and management of this rare but potentially severe condition.
Pricing Analysis of Hemophilia Drugs and Treatments in Japan
The pricing of hemophilia drugs and treatments in Japan hemophilia treatment market reflects a complex interplay between government regulations, pharmaceutical innovation, and healthcare system priorities. As of 2025, the average annual cost of treatment for a severe hemophilia A patient on prophylaxis ranges from ¥15 million to ¥25 million (approximately $100,000 to $170,000 USD), depending on the specific product and dosing regimen. This cost has seen a moderate increase of about 5% since 2023, primarily due to the introduction of more advanced, longer-acting factor concentrates. For Hemophilia B, the annual treatment costs are slightly lower, averaging between ¥12 million to ¥20 million ($80,000 to $135,000 USD), reflecting the lower dosing requirements of factor IX products.
The pricing structure in Japan hemophilia treatment market is heavily influenced by the government’s drug pricing system, which includes periodic price revisions to balance innovation incentives with healthcare sustainability. Novel therapies, such as non-factor treatments like emicizumab, have entered the market at premium prices, with annual costs reaching up to ¥30 million ($200,000 USD) for some patients. However, these higher upfront costs are often justified by improved outcomes and reduced hospitalization rates. Gene therapies, while still in clinical trials in Japan, are expected to be priced significantly higher, potentially in the range of ¥150 million to ¥200 million ($1 million to $1.3 million USD) for a one-time treatment. This pricing reflects the potential long-term benefits and cost savings over traditional therapies. The Japanese healthcare system’s comprehensive coverage ensures that patients have access to these treatments with minimal out-of-pocket expenses, typically capped at 10-30% of the total cost, with further reductions for high-cost therapies. This pricing and reimbursement structure aims to balance patient access with the sustainability of the healthcare system, encouraging pharmaceutical companies to continue investing in innovative treatments while maintaining affordability for patients.
Top 4 Drugs for Hemophilia in Japan
The hemophilia treatment market in Japan is characterized by a diverse array of therapeutic options, with four key drugs and treatment types standing out for their efficacy and adoption rates. Among the top drugs, recombinant factor VIII concentrates remain a cornerstone of Hemophilia A treatment. Products like Advate and Kogenate FS have demonstrated high efficacy in preventing bleeding episodes, with an average reduction in annual bleed rates of 95% when used prophylactically. These products are widely adopted, with approximately 70% of severe Hemophilia A patients in Japan using recombinant factor VIII for prophylaxis.
Emicizumab (Hemlibra) has emerged as a game-changing therapy for Hemophilia A patients in the Japan hemophilia treatment market, particularly those with inhibitors. Its unique mechanism of action, mimicking factor VIII function, has led to a significant reduction in bleeding events, with studies showing an 87% decrease in treated bleeds compared to previous treatment regimens. The convenience of subcutaneous administration and less frequent dosing has driven its adoption, with an estimated 40% of eligible patients in Japan now using emicizumab as of 2025. For Hemophilia B, recombinant factor IX concentrates like Alprolix have become the standard of care. These extended half-life products have allowed for less frequent infusions while maintaining high efficacy, with patients experiencing an average of 3 spontaneous bleeding episodes per year, down from 15-20 with older treatments. The adoption rate for extended half-life factor IX products in Japan has reached 60% among Hemophilia B patients.
Desmopressin (DDAVP) remains an important option for mild Hemophilia A cases, offering a non-factor alternative that can increase factor VIII levels by 2-4 times baseline. While its use is more limited, it is particularly valuable for managing minor bleeding episodes or preparing for minor surgeries in about 15% of Hemophilia A patients in Japan.
Need a detailed report walkthrough? Request an online presentation from our analyst: https://www.astuteanalytica.com/speak-analyst/japan-hemophilia-treatment-market
Key Developments in Hemophilia Treatment: Japanese Innovations
Japan has been at the forefront of several key developments in hemophilia treatment market, showcasing a commitment to innovation and improved patient care. One of the most significant advancements has been the development and approval of ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement therapy. This novel treatment, developed through collaboration between Japanese and international researchers, has demonstrated exceptional efficacy in clinical trials. Patients receiving ALTUVIIIO experienced a remarkable 77% reduction in annualized bleeding rates compared to previous factor VIII therapies, with 42% of participants achieving zero bleeds over a 52-week period. The once-weekly dosing schedule of ALTUVIIIO represents a significant improvement in convenience and quality of life for patients, potentially increasing adherence to prophylactic regimens.
Another notable development in the hemophilia treatment market is the progress in gene therapy trials for both Hemophilia A and B. Japanese research institutions, in collaboration with global pharmaceutical companies, have been actively participating in these trials. Preliminary results from a Phase III trial for Hemophilia B gene therapy showed that 94% of participants achieved factor IX activity levels in the mild hemophilia range or higher after a single infusion. For Hemophilia A, a similar trial demonstrated that 87% of treated patients maintained factor VIII levels above 5% for at least two years post-treatment, significantly reducing the need for factor replacement therapy. These advancements in gene therapy hold the promise of long-term or potentially curative treatments for hemophilia patients in Japan.
In the non-factor therapies segment, Japanese researchers have made significant contributions to the development of bispecific antibodies like emicizumab. The AGEHA study, a Japanese Phase III clinical trial, evaluated the use of emicizumab in patients with acquired hemophilia A, a rare but serious condition. The study results showed that 90% of patients achieved effective bleeding control without the need for additional hemostatic treatment, marking a significant advancement in managing this challenging form of hemophilia. These developments underscore Japan’s role in driving innovation in hemophilia treatment, with a focus on improving efficacy, reducing treatment burden, and addressing unmet needs in the patient population.
Targeted Patient Population: Demographics and Treatment Strategies
- Demographics
The targeted patient population for hemophilia treatment market in Japan encompasses a diverse group, with strategies tailored to address the specific needs of different demographics. As of 2025, the hemophilia patient population in Japan is estimated at around 7,000 individuals, with approximately 5,750 affected by Hemophilia A and 1,200 by Hemophilia B. The age distribution of this population has shifted over the years, with a growing proportion of adult and elderly patients due to improved life expectancy. Currently, about 25% of hemophilia patients in Japan are under 18 years old, 50% are between 18 and 50 years, and 25% are over 50 years of age.
Treatment strategies are carefully tailored to these different age groups. For pediatric patients, who make up about 1,750 of the total hemophilia population, the focus is on early initiation of prophylactic treatment to prevent joint damage and ensure normal physical development. Approximately 90% of severe hemophilia children in Japan are on prophylactic regimens, with a trend towards starting treatment as early as 1 year of age. For adult patients, who constitute the largest group at around 3,500 individuals, treatment strategies often involve balancing prophylaxis with on-demand treatment based on lifestyle and activity levels. About 75% of adult patients with severe hemophilia are on some form of prophylactic regimen, with the remainder opting for on-demand treatment or modified prophylaxis schedules.
- Treatment Strategies
The growing elderly hemophilia population, now numbering around 1,750 patients, presents unique challenges for the hemophilia treatment market growth. These patients often have comorbidities such as cardiovascular disease or arthropathy, necessitating careful management of their hemophilia treatment. Approximately 60% of elderly hemophilia patients in Japan are on tailored prophylactic regimens, with dosing adjusted to account for age-related changes in pharmacokinetics and reduced physical activity. Additionally, there is an increasing focus on managing acquired hemophilia in the elderly population, with an estimated 100 new cases diagnosed annually. Treatment strategies for this group often involve immunosuppressive therapy in addition to hemostatic management, with about 80% of patients achieving complete remission within a year of diagnosis. These targeted approaches reflect the evolving landscape of hemophilia care in Japan, emphasizing personalized treatment plans that consider age, severity, and individual patient needs.
Healthcare Infrastructure and Patient Access to Hemophilia Care
Japan’s healthcare infrastructure in hemophilia treatment market is characterized by a comprehensive network of specialized treatment centers and a robust national health insurance system. As of 2025, there are approximately 100 hemophilia treatment centers (HTCs) across Japan, providing specialized care and comprehensive management for patients with bleeding disorders These centers are strategically distributed to ensure accessibility, with at least one HTC in each of Japan’s 47 prefectures. The HTCs are equipped with multidisciplinary teams including hematologists, nurses, physiotherapists, and social workers, offering a holistic approach to hemophilia management. On average, each HTC serves about 70 hemophilia patients, although this number varies significantly between urban and rural areas.
Patient access to hemophilia care in Japan is facilitated by the country’s universal health insurance system, which covers the majority of treatment costs. Under this system in the hemophilia treatment market, patients typically pay only 10-30% of their medical expenses, with a monthly cap on out-of-pocket costs that varies based on income for high-cost treatments like factor concentrates or novel therapies, additional subsidies are available through the Specified Disease Treatment Research Program, which further reduces the financial burden on patients. As a result, approximately 98% of hemophilia patients in Japan have access to prophylactic treatment when clinically indicated, one of the highest rates globally.
Japan Hemophilia Treatment Market Major Players:
- KM Biologics
- Takeda Pharmaceuticals
- Chugai Pharmaceuticals
- Other Prominent Players
Key Segmentation:
By Type
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
By Product
- Recombinant coagulation factor concentrates
- Plasma-derived coagulation factor concentrates
- Desmopressin
- Antifibrinolytic agents
- Gene therapy products
- Others
By Patient
- Pediatric
- 0 to 4 yrs
- 5 to 13 yrs
- 14 to18 yrs
- Adult
- 19 to 44 yrs
- 45+ yrs
By Treatment Type
- On-Demand Treatment
- Prophylactic Treatment
- Immune Tolerance Induction (ITI) Therapy
By Route of Administration
- Intravenous
- Subcutaneous
By End user
- Hospitals
- Specialty Clinics
- Home Care Settings
- Hemophilia Treatment Centers (HTCs)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Inquire about this report before purchasing: https://www.astuteanalytica.com/inquire-before-purchase/japan-hemophilia-treatment-market
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/
Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
